Photoaging Clinical Trial
Official title:
A Prospective Study Evaluating the Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatment.
Verified date | November 2023 |
Source | Bausch Health Americas, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective study of up to 30 subjects designed to assess the safety and effectiveness of a non-ablative fractional laser combination wavelength treatment for general resurfacing of photoaged skin. All study subjects will be treated on the whole face with the CLEAR + BRILLIANT TOUCH(R) 1440-nm and 1927-nm handpieces. Subjects will be treated with a consecutive series of four (4) treatments spaced 1 month apart, along with follow-up study visits at one (1) and three (3) months after final treatment.
Status | Completed |
Enrollment | 28 |
Est. completion date | November 18, 2022 |
Est. primary completion date | November 18, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Male or female. 2. 18 to 65 years of age. 3. Written and oral informed consent must be obtained. 4. No more than Mild (I) to Moderate (II) classification on Glogau Photodamage Scale. 5. Fitzpatrick skin types I-VI. 6. Fitzpatrick wrinkle & elastosis scale class I-II, score 1-6 (fine wrinkles and mild elastosis). 7. Ability to read, understand and sign the informed consent form. 8. Agree not to take any new medications (unless prescribed by the study investigator) or undergo any other procedures that may potentially treat photodamaged skin (any other aesthetic treatments) during the study. Exclusion Criteria: 1. Pregnant, breastfeeding, or planning to become pregnant during the study. 2 History of any type of allergic reaction to lidocaine. 3. Recent and/or active localized or systemic infections. 4. Diagnosis/possibility of actinic keratosis, melasma, rosacea, or other significant skin conditions (e.g. skin cancer, active infections, cold sores, open wounds, rashes, burns, inflammation eczema, psoriasis). 5. Predisposition to keloid formation or excessive scarring. 6. Diagnosis of a condition that may compromise the immune system, such as: HIV, lupus, scleroderma, and/or systemic infections. 7. Known sensitivity to light or photosensitizing agents/medications are being taken. 8. Systemic steroids (e.g. prednisone, dexamethasone), which should be rigorously avoided prior to and throughout course of the treatment. 9. Use of retinoids less than 2 weeks prior to or during the study to completion. 10. Individuals undergoing Accutaneâ„¢ treatment or drugs in a similar class. 11. Having skin that is still recovering from a cosmetic procedure: such as a chemical peel, or mechanical peel, or laser resurfacing within the previous 6 months. 12. Having had Botox injections, neurotoxin injections, or dermal fillers (such as collagen) within the past four months. 13. Sunburn and/or recent sun exposure on the treatment area in the last 2 weeks. 14. Subjects must agree to seek the advice of their medical doctor regarding any known or suspicious skin condition before laser treatment. 15. Any condition or situation that would prevent the subject from safely completing all protocol requirements for participation. 16. Subjects who are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function. |
Country | Name | City | State |
---|---|---|---|
United States | Bausch Site 001 | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
Bausch Health Americas, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Improvement in Photoaging Damage Appearance at 3 Months Post Treatment | Improvement in the appearance of at least one measurement of photoaging damage (fine wrinkles, skin texture, dyschromia/pigment, skin radiance, pore size or overall appearance), each assessed by the investigator using the quartile improvement score comparing standard 2D baseline photograph captured via Canfield VISIA CA system. The Quartile Improvement Score ranges from 0 to 4, with 0 = 0%, 1 = 1% to 25%, 2 = 26% to 50%, 3 = 51% to 75%, and 4 = 76% to 100% improvement. Higher scores indicated greater improvement. | 3 months post treatment, up to 7 months | |
Secondary | Mean Improvement in Photoaging Damage Appearance at 1 Month Post Treatment | Improvement in the appearance of at least one measurement of photoaging damage (fine wrinkles, skin texture, dyschromia/pigment, skin radiance, pore size or overall appearance), each assessed by the investigator using the quartile improvement score comparing standard 2D baseline photograph captured via Canfield VISIA CA system. The Quartile Improvement Score ranges from 0 to 4, with 0 = 0%, 1 = 1% to 25%, 2 = 26% to 50%, 3 = 51% to 75%, and 4 = 76% to 100% improvement. Higher scores indicated greater improvement. | 1 month post treatment, up to 5 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05271136 -
A Clinical Study to Evaluate the Efficacy of an Anti-Aging Serum
|
N/A | |
Completed |
NCT05514782 -
A Clinical Study to Evaluate the Long-Term Efficacy and Tolerability of a Daily Anti-Aging Daily Serum
|
N/A | |
Completed |
NCT04911374 -
An Open-Label Clinical Study to Evaluate the Efficacy of a Face Cream and Eye Cream
|
N/A | |
Completed |
NCT04586816 -
Randomized, Double-Blind Evaluation of Maple Leaf Extract (Maplifa) for Photoaging
|
N/A | |
Not yet recruiting |
NCT05004909 -
Effectivity of 1 Finger Tip Unit Compared to 2 Finger Tip Units 0.05% Tretinoin Cream
|
N/A | |
Completed |
NCT05039723 -
Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational
|
Phase 4 | |
Completed |
NCT06366503 -
Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation
|
N/A | |
Not yet recruiting |
NCT06096649 -
The Effects of Zinc Di-(Dibutyryl Lisinate) on Skin Health and the Skin Microbiome in Photoaged Skin
|
N/A | |
Completed |
NCT03661697 -
Combination Versus Laser Treatment Only
|
N/A | |
Completed |
NCT03948945 -
Efficacy and Safety of Profile HaloTM Mixed Fractional Laser on Treating of Facial and Neck Photoaging.
|
N/A | |
Completed |
NCT06148558 -
A Twelve Week Clinical Study to Evaluate the Efficacy and Tolerability of a Sunscreen Moisturizer SPF 50+
|
N/A | |
Enrolling by invitation |
NCT06188338 -
A 56-day Clinical Study on Facial Skin Rejuvenation
|
N/A | |
Recruiting |
NCT06195605 -
Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin
|
N/A | |
Not yet recruiting |
NCT04869852 -
Effects of Mango Intake on Skin Health and Gut Microbiome Changes in Postmenopausal Women
|
N/A | |
Not yet recruiting |
NCT02126644 -
The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Photoaging
|
Phase 2 | |
Active, not recruiting |
NCT01372566 -
Effect of Platelet Rich Plasma on Photoaged Skin
|
Phase 1/Phase 2 | |
Unknown status |
NCT00842907 -
Efficacy and Safety of Oral Isotretinoin for Cutaneous Photodamage
|
Phase 2 | |
Completed |
NCT03112863 -
Comparison of the Cosmetic Effects of Bakuchiol and Retinol
|
Early Phase 1 | |
Recruiting |
NCT05386368 -
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
|
Phase 4 | |
Recruiting |
NCT05471947 -
TCA 15% Chemical Peel for Improvement in Hand Lentigines
|
Phase 4 |